Ipca Laboratories Limited

“IPCA is a vertically integrated Indian pharma company with a durable domestic franchise and a credible but unproven US re-entry story; post-FDA remediation, the structural outlook is genuinely improving, but at 28.3x forward earnings the market already prices near-perfect execution, leaving limited margin of safety against the binary risk of regulatory recidivism that could permanently impair the international thesis — the right action is to track for a better entry around 22-24x forward rather than commit capital today.”